临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展

樊庆达; 丛斌斌; 陈玉光; 段宝伟; 王永胜

doi:10.19401/j.cnki.1007-3639.2023.02.011

您当前的位置：

首页 >

文章列表页 >

临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展

综述 | 更新时间：2025-12-31

- 临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展
- Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients
- 中国癌症杂志 2023年33卷第2期页码：174-180
- 作者机构：
  
  1. 山东第一医科大学（山东省医学科学院）研究生部，山东济南 250118
  2. 山东省肿瘤防治研究院（山东省肿瘤医院）乳腺病中心，山东第一医科大学（山东省医学科学院），山东济南 250117
  3. 泰安市肿瘤防治院乳腺外科，山东泰安 271000
- 作者简介：
  
  [ "樊庆达（ORCID: 0000-0001-5815-131X），硕士研究生。" ]
  王永胜（ORCID: 0000-0001-6252-684X），博士，主任医师，山东省肿瘤医院乳腺病中心主任。
- 基金信息：
  
  国家自然科学基金(81672638);山东省自然科学基金(ZR2021QH164)
- DOI：10.19401/j.cnki.1007-3639.2023.02.011
  中图分类号： R737.9
- 收稿：2022-10-26，
  
  修回：2022-11-28，
  
  纸质出版：2023-02-28
- 稿件说明：
移动端阅览
樊庆达, 丛斌斌, 陈玉光, 等. 临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展[J]. 中国癌症杂志, 2023,33(2):174-180.

Qingda FAN, Binbin CONG, Yuguang CHEN, et al. Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients[J]. China Oncology, 2023, 33(2): 174-180.
樊庆达, 丛斌斌, 陈玉光, 等. 临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展[J]. 中国癌症杂志, 2023,33(2):174-180. DOI： 10.19401/j.cnki.1007-3639.2023.02.011.

Qingda FAN, Binbin CONG, Yuguang CHEN, et al. Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients[J]. China Oncology, 2023, 33(2): 174-180. DOI： 10.19401/j.cnki.1007-3639.2023.02.011.

摘要

在优效系统治疗和精准放疗的时代背景下，乳腺癌新辅助治疗（neoadjuvant treatment，NAT）有助于乳房肿瘤降期实现保乳和腋窝降期，使患者豁免腋窝淋巴结清扫（axillary lymph node dissection，ALND）。目前，在临床腋窝淋巴结阳性的患者中，人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）阳性和三阴性乳腺癌（triple-negative breast cancer，TNBC）亚型接受NAT后可达到较高的腋窝病理学完全缓解率（axillary nodal pathologic complete response，apCR），有望实现腋窝局部降阶梯处理，相关指南与专家共识推荐初始临床淋巴结阴性（clinical lymph node negative，cN

）的患者NAT后前哨淋巴结（sentinel lymph node，SLN）阴性可行前哨淋巴结活检（sentinel lymph node biopsy，SLNB）替代ALND，NAT后SLN存在较低肿瘤残留负荷的患者可考虑放疗替代ALND。初始临床淋巴结阳性（clinical lymph node positive，cN

）患者NAT后转为ycN

接受常规SLNB的可行性依然受到质疑，主要障碍是NAT后SLNB的假阴性率较高，不能准确预测腋窝肿瘤细胞残留且不能明确术后腋窝复发转移风险。在联合示踪、SLN检出数目≥3枚、临床腋窝转移肿瘤负荷较低的条件下，SLNB的假阴性率可能会满足临床需求。然而，由于肿瘤细胞阻塞淋巴管，影响蓝染料或放射性核素的引流等原因，NAT后SLNB的质量并不能得到有效的改善。因此，需要实现NAT后SLNB技术的优化。靶向腋窝淋巴结切除术（targeted axillary lymph node dissection，TAD）是对NAT前穿刺证实转移的腋窝淋巴结放置标记夹并在NAT后SLNB时靶向检出的精准外科手术操作技术，可以进一步降低NAT后SLNB的假阴性率、实现NAT后腋窝淋巴结肿瘤残留负荷的准确评估。对于NAT后转阴的乳腺癌患者，TAD有望成为NAT后腋窝降期患者安全、可靠的腋窝分期技术。本文就初始cN

患者NAT后腋窝降阶梯处理及TAD研究进展进行综述。

Abstract

In the era of effective systemic therapy and precise radiotherapy

neoadjuvant treatment (NAT) for breast cancer can de-escalate breast cancer treatment to conserve breast and spare

axillary lymph node dissection (ALND). At present

high axillary nodal pathologic complete response (apCR) is achieved in patients with human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC)

and it is hopeful to realize the axillary de-escalation management. It is recommended that sentinel lymph node (SLN) biopsy (SLNB) is a feasible alternative to ALND in primary clinical lymph node negative (cN

) patients

and the presence of lower residual tumor burden in SLN after NAT may be considered as a replacement for ALND with radiotherapy. The feasibility of the patients with initial clinical lymph node positive (cN

) turning to conventional SLNB after NAT is still being questioned. The main obstacle is the high false negative rate of SLNB after NAT

residual tumor cells in the axilla cannot be accurately predicted

and the risk of postoperative axillary recurrence and metastasis cannot be determined. The false negative rate of SLNB may meet the clinical requirement under the condition of combined tracing

more than 3 SLNs detected

and lower clinical axillary metastatic tumor burden. However

the quality of SLNB after NAT cannot be effectively improved due to tumor cells blocking lymphatic vessels and affecting the drainage of blue dye or radionuclide. Therefore

optimization of SLNB technology needs to be implemented after NAT. Targeted axillary lymph node dissection (TAD) is a precise surgical procedure for the detection of metastatic axillary lymph nodes

and clips were placed on the metastatic lymph nodes before NAT and targeted to detect the lymph nodes after NAT. It can further reduce the false negative rate of SLNB after NAT and improve the accurate assessment of residual tumor burden in axillary lymph nodes after NAT. TAD is expected to be a safe and reliable axillary staging technique for breast cancer patients after NAT. This article reviewed the de-escalation treatment of NAT in initial cN+ patients and the research progress of TAD.

关键词

Keywords

references

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

THOMSSEN C , BALIC M , HARBECK N , et al. St. Gallen/Vienna 2021: a brief summary of the consensus discussion on customizing therapies for women with early breast cancer [J ] . Breast Care (Basel) , 2021 , 16 ( 2 ): 135 - 143 . DOI: 10.1159/000516114 http://doi.org/10.1159/000516114 https://www.karger.com/Article/FullText/516114 https://www.karger.com/Article/FullText/516114

CAUDLE A S , YANG W T , KRISHNAMURTHY S , et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection [J ] . J Clin Oncol , 2016 , 34 ( 10 ): 1072 - 1078 . DOI: 10.1200/JCO.2015.64.0094 http://doi.org/10.1200/JCO.2015.64.0094

SWARNKAR P K , TAYEH S , MICHELL M J , et al. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis [J ] . Cancers (Basel) , 2021 , 13 ( 7 ): 1539 . DOI: 10.3390/cancers13071539 http://doi.org/10.3390/cancers13071539 https://www.mdpi.com/2072-6694/13/7/1539 https://www.mdpi.com/2072-6694/13/7/1539

DONKER M , STRAVER M E , WESSELING J , et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure [J ] . Ann Surg , 2015 , 261 ( 2 ): 378 - 382 . DOI: 10.1097/SLA.0000000000000558 http://doi.org/10.1097/SLA.0000000000000558

BOUGHEY J C , SUMAN V J , MITTENDORF E A , et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial [J ] . JAMA , 2013 , 310 ( 14 ): 1455 - 1461 . DOI: 10.1001/jama.2013.278932 http://doi.org/10.1001/jama.2013.278932

SIMONS J M , VAN NIJNATTEN T J A , VAN DER POL C C , et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis [J ] . Ann Surg , 2019 , 269 ( 3 ): 432 - 442 . DOI: 10.1097/SLA.0000000000003075 http://doi.org/10.1097/SLA.0000000000003075

BOILEAU J F , POIRIER B , BASIK M , et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study [J ] . J Clin Oncol , 2015 , 33 ( 3 ): 258 - 264 .

KUEHN T , BAUERFEIND I , FEHM T , et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study [J ] . Lancet Oncol , 2013 , 14 ( 7 ): 609 - 618 . DOI: 10.1016/S1470-2045(13)70166-9 http://doi.org/10.1016/S1470-2045(13)70166-9

BI Z , LIU J J , CHEN P , et al. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla [J ] . Breast Cancer , 2019 , 26 ( 3 ): 373 - 377 . DOI: 10.1007/s12282-018-00934-3 http://doi.org/10.1007/s12282-018-00934-3

SHI Z Q , WANG X E , QIU P F , et al. Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy [J ] . Gland Surg , 2021 , 10 ( 1 ): 166 - 174 . DOI: 10.21037/gs-20-573 http://doi.org/10.21037/gs-20-573

BARRON A U , HOSKIN T L , DAY C N , et al. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy [J ] . JAMA Surg , 2018 , 153 ( 12 ): 1120 - 1126 . DOI: 10.1001/jamasurg.2018.2696 http://doi.org/10.1001/jamasurg.2018.2696

KANTOR O , SIPSY L M , YAO K , et al. A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer [J ] . Ann Surg Oncol , 2018 , 25 ( 5 ): 1304 - 1311 . DOI: 10.1245/s10434-018-6345-5 http://doi.org/10.1245/s10434-018-6345-5

郑卫真 , 孙菊杰 , 刘雁冰 , 等 . 乳腺癌新辅助化疗后腋窝淋巴结病理学完全缓解预测模型的验证与改良研究 [J ] . 中国癌症杂志 , 2019 , 29 ( 6 ): 445 - 451 . DOI: 10.19401/j.cnki.1007-3639.2019.06.008 http://doi.org/10.19401/j.cnki.1007-3639.2019.06.008

ZHENG W Z , SUN J J , LIU Y B , et al. Validation and modification study of axillary node pathologic complete response predictive model after neoadjuvant chemotherapy for breast cancer [J ] . China Oncol , 2019 , 29 ( 6 ): 445 - 451 .

KUEMMEL S , HEIL J , RUELAND A , et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients [J ] . Ann Surg , 2022 , 276 ( 5 ): e553 -e562. DOI: 10.1097/SLA.0000000000004572 http://doi.org/10.1097/SLA.0000000000004572 https://journals.lww.com/10.1097/SLA.0000000000004572 https://journals.lww.com/10.1097/SLA.0000000000004572

BRACKSTONE M , BALDASSARRE F G , PERERA F E , et al. Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO guideline [J ] . J Clin Oncol , 2021 , 39 ( 27 ): 3056 - 3082 . DOI: 10.1200/JCO.21.00934 http://doi.org/10.1200/JCO.21.00934 https://ascopubs.org/doi/10.1200/JCO.21.00934 https://ascopubs.org/doi/10.1200/JCO.21.00934

GRADISHAR W J , MORAN M S , ABRAHAM J , et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2022 , 20 ( 6 ): 691 - 722 . DOI: 10.6004/jnccn.2022.0030 http://doi.org/10.6004/jnccn.2022.0030 https://jnccn.org/view/journals/jnccn/20/6/article-p691.xml https://jnccn.org/view/journals/jnccn/20/6/article-p691.xml

MARISCAL MARTÍNEZ A , VIVES ROSELLÓ I , SALAZAR GÓMEZ A , et al. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer [J ] . Surg Oncol , 2021 , 36 : 28 - 33 . DOI: 10.1016/j.suronc.2020.11.013 http://doi.org/10.1016/j.suronc.2020.11.013

SIMONS J M , SCOGGINS M E , KUERER H M , et al. Prospective registry trial assessing the use of magnetic seeds to locate clipped nodes after neoadjuvant chemotherapy for breast cancer patients [J ] . Ann Surg Oncol , 2021 , 28 ( 8 ): 4277 - 4283 . DOI: 10.1245/s10434-020-09542-y http://doi.org/10.1245/s10434-020-09542-y

SUN J , HENRY D A , CARR M J , et al. Feasibility of axillary lymph node localization and excision using radar reflector localization [J ] . Clin Breast Cancer , 2021 , 21 ( 3 ): e189 -e193. DOI: 10.1016/j.clbc.2020.08.001 http://doi.org/10.1016/j.clbc.2020.08.001

MISBACH L S , KARIMOVA E J , CRONIN C , et al. Implementing radar reflector-guided localization of nonpalpable breast lesions: feasibility, challenges, outcomes, and lessons learned [J ] . Breast J , 2021 , 27 ( 7 ): 608 - 611 . DOI: 10.1111/tbj.v27.7 http://doi.org/10.1111/tbj.v27.7 https://onlinelibrary.wiley.com/toc/15244741/27/7 https://onlinelibrary.wiley.com/toc/15244741/27/7

LOWES S , BELL A , MILLIGAN R , et al. Use of Hologic LOCalizer radiofrequency identification (RFID) tags to localise impalpable breast lesions and axillary nodes: experience of the first 150 cases in a UK breast unit [J ] . Clin Radiol , 2020 , 75 ( 12 ): 942 - 949 . DOI: 10.1016/j.crad.2020.08.014 http://doi.org/10.1016/j.crad.2020.08.014

GERA R , TAYEH S , AL-REEFY S , et al. Evolving role of magseed in wireless localization of breast lesions: systematic review and pooled analysis of 1, 559 procedures [J ] . Anticancer Res , 2020 , 40 ( 4 ): 1809 - 1815 . DOI: 10.21873/anticanres.14135 http://doi.org/10.21873/anticanres.14135 http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.14135 http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.14135

MAN V , KWONG A . Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review [J ] . Breast Cancer Res Treat , 2021 , 186 ( 3 ): 607 - 615 . DOI: 10.1007/s10549-021-06118-6 http://doi.org/10.1007/s10549-021-06118-6

CLASSE J M , LOAEC C , GIMBERGUES P , et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study [J ] . Breast Cancer Res Treat , 2019 , 173 ( 2 ): 343 - 352 . DOI: 10.1007/s10549-018-5004-7 http://doi.org/10.1007/s10549-018-5004-7

BARRIO A V , MONTAGNA G , MAMTANI A , et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event [J ] . JAMA Oncol , 2021 , 7 ( 12 ): 1851 - 1855 . DOI: 10.1001/jamaoncol.2021.4394 http://doi.org/10.1001/jamaoncol.2021.4394

KAHLER-RIBEIRO-FONTANA S , PAGAN E , MAGNONI F , et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up [J ] . Eur J Surg Oncol , 2021 , 47 ( 4 ): 804 - 812 . DOI: 10.1016/j.ejso.2020.10.014 http://doi.org/10.1016/j.ejso.2020.10.014 https://linkinghub.elsevier.com/retrieve/pii/S0748798320308465 https://linkinghub.elsevier.com/retrieve/pii/S0748798320308465

NSABP Foundation Inc. NCT01872975. Standard or comprehensive radiation therapy in treating patients with early stage breast cancer previously treated with chemotherapy and surgery [EB/OL ] . [ 2022-9-16 ] . https://clinicaltrials.gov/ct2/show/NCT01872975 https://clinicaltrials.gov/ct2/show/NCT01872975 https://clinicaltrials.gov/ct2/show/NCT01872975.

MOO T A , EDELWEISS M , HAJIYEVA S , et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? [J ] . Ann Surg Oncol , 2018 , 25 ( 6 ): 1488 - 1494 . DOI: 10.1245/s10434-018-6429-2 http://doi.org/10.1245/s10434-018-6429-2

PILTIN M A , HOSKIN T L , DAY C N , et al. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer [J ] . Ann Surg Oncol , 2020 , 27 ( 12 ): 4795 - 4801 . DOI: 10.1245/s10434-020-08900-0 http://doi.org/10.1245/s10434-020-08900-0

Alliance for Clinical Trials in Oncology . NCT01901094 (A011202). Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy [EB/OL ] . [ 2022-9-16 ] . https://clinicaltrials.gov/ct2/show/NCT01901094 https://clinicaltrials.gov/ct2/show/NCT01901094 https://clinicaltrials.gov/ct2/show/NCT01901094.

FLORES-FUNES D , AGUILAR-JIMÉNEZ J , MARTÍNEZ-GÁLVEZ M , et al. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: preliminary results [J ] . Surg Oncol , 2019 , 30 : 52 - 57 . DOI: 10.1016/j.suronc.2019.05.019 http://doi.org/10.1016/j.suronc.2019.05.019 https://linkinghub.elsevier.com/retrieve/pii/S0960740418302949 https://linkinghub.elsevier.com/retrieve/pii/S0960740418302949

GATEK J , PETRU V , KOSAC P , et al. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer [J ] . Neoplasma , 2020 , 67 ( 6 ): 1329 - 1334 . DOI: 10.4149/neo_2020_191228N1344 http://doi.org/10.4149/neo_2020_191228N1344 http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6853&category_id=160&option=com_virtuemart http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6853&category_id=160&option=com_virtuemart

浏览量

1367

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

乳腺癌内乳前哨淋巴结活检与患者预后的相关性研究

乳腺癌前哨淋巴结阳性豁免腋窝清扫后区域淋巴结放疗的回顾性研究

早期乳腺癌局部治疗与全身治疗的进展与展望

临床查体阴性但超声检查及穿刺确诊腋窝淋巴结转移的乳腺癌前哨淋巴结活检的可行性分析

乳腺癌前哨淋巴结活检术的发展历史及研究进展